PMID- 11023981
OWN - NLM
STAT- MEDLINE
DCOM- 20001108
LR  - 20131121
IS  - 0892-6638 (Print)
IS  - 0892-6638 (Linking)
VI  - 14
IP  - 13
DP  - 2000 Oct
TI  - Anti-monocyte chemoattractant protein-1 gene therapy inhibits vascular remodeling 
      in rats: blockade of MCP-1 activity after intramuscular transfer of a mutant gene 
      inhibits vascular remodeling induced by chronic blockade of NO synthesis.
PG  - 1974-8
AB  - Monocyte chemoattractant protein-1 (MCP-1) may play an essential part in the 
      formation of arteriosclerosis by recruiting monocytes into the arterial wall. 
      Thus, we devised a new strategy for anti-MCP-1 gene therapy against 
      arteriosclerosis by transfecting an amino-terminal deletion mutant (missing the 
      amino-terminal amino acids 2 to 8) of the human MCP-1 gene into a remote organ 
      (skeletal muscles). Intramuscular transduction with the mutant MCP-1 gene blocked 
      monocyte recruitment induced by a subcutaneous injection of recombinant MCP-1. In 
      a rat model in which the chronic inhibition of endothelial nitric oxide synthesis 
      induces early vascular inflammation as well as subsequent coronary vascular 
      remodeling, this strategy suppressed monocyte recruitment into the coronary 
      vessels and the development of vascular medial thickening, but did not reduce 
      perivascular fibrosis. Thus, MCP-1 is necessary for the development of medial 
      thickening but not for fibrosis in this model. This new strategy may be a useful 
      and feasible gene therapy against arteriosclerosis.
FAU - Egashira, K
AU  - Egashira K
AD  - Department of Cardiovascular Medicine, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan. egashira@cardiol.med.kyushu-u.ac.jp
FAU - Koyanagi, M
AU  - Koyanagi M
FAU - Kitamoto, S
AU  - Kitamoto S
FAU - Ni, W
AU  - Ni W
FAU - Kataoka, C
AU  - Kataoka C
FAU - Morishita, R
AU  - Morishita R
FAU - Kaneda, Y
AU  - Kaneda Y
FAU - Akiyama, C
AU  - Akiyama C
FAU - Nishida, K I
AU  - Nishida KI
FAU - Sueishi, K
AU  - Sueishi K
FAU - Takeshita, A
AU  - Takeshita A
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - FASEB J
JT  - FASEB journal : official publication of the Federation of American Societies for 
      Experimental Biology
JID - 8804484
RN  - 0 (Chemokine CCL2)
RN  - 0 (Recombinant Proteins)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase)
RN  - EC 1.14.13.39 (Nitric Oxide Synthase Type III)
RN  - EC 1.14.13.39 (Nos3 protein, rat)
SB  - IM
MH  - Animals
MH  - Arteriosclerosis/*therapy
MH  - Chemokine CCL2/administration & dosage/*antagonists & inhibitors/genetics
MH  - Chemotaxis, Leukocyte
MH  - Coronary Vessels/drug effects
MH  - Dermis
MH  - Genetic Therapy/*methods
MH  - Injections, Intramuscular
MH  - Male
MH  - Monocytes/physiology
MH  - Muscle, Skeletal/metabolism
MH  - Mutation
MH  - Nitric Oxide
MH  - Nitric Oxide Synthase
MH  - Nitric Oxide Synthase Type III
MH  - Rats
MH  - Rats, Inbred WKY
MH  - Recombinant Proteins/administration & dosage
EDAT- 2000/10/12 11:00
MHDA- 2001/02/28 10:01
CRDT- 2000/10/12 11:00
PHST- 2000/10/12 11:00 [pubmed]
PHST- 2001/02/28 10:01 [medline]
PHST- 2000/10/12 11:00 [entrez]
AID - 14/13/1974 [pii]
AID - 10.1096/fj.00-0141com [doi]
PST - ppublish
SO  - FASEB J. 2000 Oct;14(13):1974-8. doi: 10.1096/fj.00-0141com.